Research programme: NF-kappa B inhibitors - Othera Pharmaceuticals

Drug Profile

Research programme: NF-kappa B inhibitors - Othera Pharmaceuticals

Alternative Names: OT 300 programme - Othera Pharmaceuticals; OT-304

Latest Information Update: 12 Dec 2012

Price : $50

At a glance

  • Originator Othera Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Thromboplastin inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Thrombosis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2012 Colby Pharmaceuticals acquires Othera Pharmaceuticals
  • 23 Aug 2011 No development reported - Preclinical for Thrombosis in USA (PO)
  • 23 Aug 2011 No development reported - Preclinical for Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top